# A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

> **NCT02494258** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 5 (actual)

## Conditions studied

- Hematologic Neoplasm
- Neoplasms
- Hematologic Malignancies

## Interventions

- **DRUG:** CC-486

## Key facts

- **NCT ID:** NCT02494258
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-22
- **Primary completion:** 2025-04-14
- **Final completion:** 2025-04-14
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02494258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02494258, "A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02494258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*